MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer
作者： Bernard Paule , Vincent Castagne , Véronique Picard , Raphaël Saffroy , René Adam
DOI: 10.1007/S12032-009-9336-3
关键词:
摘要: The aim of the study was to evaluate influence MDR1 C3435T polymorphism on therapeutic response in 23 patients treated with cetuximab plus irinotecan for refractory liver metastatic colorectal cancer considering their KRAS status. Indeed, and its active metabolite (SN-38) are both substrates P-glycoprotein (P-gp) encoded by MDR1. Patients received up progression. overall survival 55% at 10 months. Overall, four had an undetermined status two mutated were progression disease. treatment observed after 3 months among 17 wild-type patients. Two presented a progressive disease (1 TT 1 CT), eight stable (5 CC 3CT) five partial (3 2 CT). Importantly, (2 TT) complete still alive 5 years starting treatment, which suggests that combination 3435 may be factor good prognosis. These results suggest EGFR inhibition overcome this resistance abrogating drug efflux depending polymorphism. Among resistant irinotecan, it is possible use association obtain resection hepatic metastases necessary improve survival.
springer.com
sci-hub.se 参考文章(29)
Kazuhiko Arimori, Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharmaceutical Research. ,vol. 20, pp. 910- 917 ,(2003) , 10.1023/A:1023847521767
Pierre Laurent-Puig, Astrid Lièvre, Facteurs prédictifs de réponse aux traitements anti-REGF dans le cancer colorectal Bulletin Du Cancer. ,vol. 95, pp. 133- 140 ,(2008) , 10.1684/BDC.2008.0551
Yuichi Sugiyama, Xiao-Yan Chu, Yukio Kato, Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Drug Metabolism and Disposition. ,vol. 27, pp. 440- 441 ,(1999)
R. Adam, T. Aloia, F. Levi, D.A. Wicherts, R.J. de Haas, B. Paule, M.P. Bralet, M. Bouchahda, D. Machover, M. Ducreux, V. Castagne, D. Azoulay, D. Castaing, Résection hépatique après traitement par agents ciblés de métastases hépatiques initialement non résécables n’ayant pas répondu à une chimiothérapie conventionnelle Journal De Chirurgie. ,vol. 145, pp. 76- ,(2008) , 10.1016/S0021-7697(08)70284-9
Roberto Canaparo, Anna Nordmark, Niklas Finnström, Stefan Lundgren, Janeric Seidegård, Bengt Jeppsson, Robert J. Edwards, Alan R. Boobis, Anders Rane, Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples. Basic & Clinical Pharmacology & Toxicology. ,vol. 100, pp. 240- 248 ,(2007) , 10.1111/J.1742-7843.2006.00023.X
Howard L. McLeod, Cristi R. King, Sharon Marsh, Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies. Clinical Colorectal Cancer. ,vol. 4, ,(2004) , 10.3816/CCC.2004.S.007
C. Chu, C. Abbara, M.S. Noël-Hudson, L. Thomas-Bourgneuf, P. Gonin, R. Farinotti, L. Bonhomme-Faivre, Disposition of everolimus in mdr1a−/1b− mice and after a pre-treatment of lapatinib in Swiss mice Biochemical Pharmacology. ,vol. 77, pp. 1629- 1634 ,(2009) , 10.1016/J.BCP.2009.02.013
Marian B. Meyers, Peter Yu, John Mendelsohn, Crosstalk between epidermal growth factor receptor and P-glycoprotein in actinomycin D-resistant Chinese hamster lung cells Biochemical Pharmacology. ,vol. 46, pp. 1841- 1848 ,(1993) , 10.1016/0006-2952(93)90591-J
Lalitha Iyer, Jacqueline Ramírez, Dale Shepard, Christopher Bingham, Dieter-Kurt Hossfeld, Mark Ratain, Ulrich Mayer, Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemotherapy and Pharmacology. ,vol. 49, pp. 336- 341 ,(2002) , 10.1007/S00280-001-0420-4
Laurence Bonhomme-Faivre, Aurore Devocelle, Faouzi Saliba, Skander Chatled, Jean Maccario, Robert Farinotti, V??ronique Picard, Mdr-1 C3435t Polymorphism Influences Cyclosporine A Dose Requirement in Liver-transplant Recipients Transplantation. ,vol. 78, pp. 21- 25 ,(2004) , 10.1097/01.TP.0000130981.55654.78